Venetoclax is safe and efficacious in relapsed/refractory AML

Chezi Ganzel; Ron Ram; Alexander Gural; Ofir Wolach; Sharon Gino-Moor; Vladimir Vainstein; Boaz Nachmias; Arie Apel; Maya Koren-Michowitz; Oren Pasvolsky; Ronit Yerushalmi; Ivetta Danylesko; Yosef Cohen; Galit Peretz; Yakir Moshe; Miri Zektser; Shay Yeganeh; Jacob M. Rowe; Yishai Ofran

doi:10.1080/10428194.2020.1761964

Venetoclax is safe and efficacious in relapsed/refractory AML

Chezi Ganzel, Ron Ram, Alexander Gural, Ofir Wolach, Sharon Gino-Moor, Vladimir Vainstein, Boaz Nachmias, Arie Apel, Maya Koren-Michowitz, Oren Pasvolsky, Ronit Yerushalmi, Ivetta Danylesko, Yosef Cohen, Galit Peretz, Yakir Moshe, Miri Zektser, Shay Yeganeh, Jacob M. Rowe, Yishai Ofran

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Abstract

Data from 11 Israeli centers, where venetoclax was used for relapsed/refractory AML after intensive chemotherapy, were retrospectively collected. During 2016–2019, forty patients were identified. Median age was 67 years (21–82), 60% males, median of 2(1–4) prior lines of treatment and 42% relapsed after allogeneic transplant. 62.5% of the patients received the venetoclax with hypomethylating agents and 22.5% with low dose cytarabine. Median follow-up was 5.5 months. Of the 29 patients who survived for more than two cycles of therapy, 22 (76%) achieved neutrophil recovery and 59% (n = 17) recovered also their platelet count. In 15 (52% of those who survived > 2 months), CR/CRi was confirmed by bone marrow examination. The median OS from venetoclax initiation of all the patients and of those who survived more than 2 months was 5.5 and 6.5 months, respectively. In conclusion, this study demonstrates that venetoclax is safe and active also in AML patients with advanced disease.

Original language	English (US)
Pages (from-to)	2221-2225
Number of pages	5
Journal	Leukemia and Lymphoma
Volume	61
Issue number	9
DOIs	https://doi.org/10.1080/10428194.2020.1761964
State	Published - Jul 28 2020
Externally published	Yes

Keywords

Acute myeloid leukemia
refractory
relapse
venetoclax

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1080/10428194.2020.1761964

Cite this

Ganzel, C., Ram, R., Gural, A., Wolach, O., Gino-Moor, S., Vainstein, V., Nachmias, B., Apel, A., Koren-Michowitz, M., Pasvolsky, O., Yerushalmi, R., Danylesko, I., Cohen, Y., Peretz, G., Moshe, Y., Zektser, M., Yeganeh, S., Rowe, J. M., & Ofran, Y. (2020). Venetoclax is safe and efficacious in relapsed/refractory AML. Leukemia and Lymphoma, 61(9), 2221-2225. https://doi.org/10.1080/10428194.2020.1761964

Ganzel, C, Ram, R, Gural, A, Wolach, O, Gino-Moor, S, Vainstein, V, Nachmias, B, Apel, A, Koren-Michowitz, M, Pasvolsky, O, Yerushalmi, R, Danylesko, I, Cohen, Y, Peretz, G, Moshe, Y, Zektser, M, Yeganeh, S, Rowe, JM & Ofran, Y 2020, 'Venetoclax is safe and efficacious in relapsed/refractory AML', Leukemia and Lymphoma, vol. 61, no. 9, pp. 2221-2225. https://doi.org/10.1080/10428194.2020.1761964

@article{d748971a653c4f73958847af498e7be2,

title = "Venetoclax is safe and efficacious in relapsed/refractory AML",

abstract = "Data from 11 Israeli centers, where venetoclax was used for relapsed/refractory AML after intensive chemotherapy, were retrospectively collected. During 2016–2019, forty patients were identified. Median age was 67 years (21–82), 60% males, median of 2(1–4) prior lines of treatment and 42% relapsed after allogeneic transplant. 62.5% of the patients received the venetoclax with hypomethylating agents and 22.5% with low dose cytarabine. Median follow-up was 5.5 months. Of the 29 patients who survived for more than two cycles of therapy, 22 (76%) achieved neutrophil recovery and 59% (n = 17) recovered also their platelet count. In 15 (52% of those who survived > 2 months), CR/CRi was confirmed by bone marrow examination. The median OS from venetoclax initiation of all the patients and of those who survived more than 2 months was 5.5 and 6.5 months, respectively. In conclusion, this study demonstrates that venetoclax is safe and active also in AML patients with advanced disease.",

keywords = "Acute myeloid leukemia, refractory, relapse, venetoclax",

author = "Chezi Ganzel and Ron Ram and Alexander Gural and Ofir Wolach and Sharon Gino-Moor and Vladimir Vainstein and Boaz Nachmias and Arie Apel and Maya Koren-Michowitz and Oren Pasvolsky and Ronit Yerushalmi and Ivetta Danylesko and Yosef Cohen and Galit Peretz and Yakir Moshe and Miri Zektser and Shay Yeganeh and Rowe, {Jacob M.} and Yishai Ofran",

note = "Publisher Copyright: {\textcopyright} 2020 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2020",

month = jul,

day = "28",

doi = "10.1080/10428194.2020.1761964",

language = "English (US)",

volume = "61",

pages = "2221--2225",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "9",

}

TY - JOUR

T1 - Venetoclax is safe and efficacious in relapsed/refractory AML

AU - Ganzel, Chezi

AU - Ram, Ron

AU - Gural, Alexander

AU - Wolach, Ofir

AU - Gino-Moor, Sharon

AU - Vainstein, Vladimir

AU - Nachmias, Boaz

AU - Apel, Arie

AU - Koren-Michowitz, Maya

AU - Pasvolsky, Oren

AU - Yerushalmi, Ronit

AU - Danylesko, Ivetta

AU - Cohen, Yosef

AU - Peretz, Galit

AU - Moshe, Yakir

AU - Zektser, Miri

AU - Yeganeh, Shay

AU - Rowe, Jacob M.

AU - Ofran, Yishai

PY - 2020/7/28

Y1 - 2020/7/28

N2 - Data from 11 Israeli centers, where venetoclax was used for relapsed/refractory AML after intensive chemotherapy, were retrospectively collected. During 2016–2019, forty patients were identified. Median age was 67 years (21–82), 60% males, median of 2(1–4) prior lines of treatment and 42% relapsed after allogeneic transplant. 62.5% of the patients received the venetoclax with hypomethylating agents and 22.5% with low dose cytarabine. Median follow-up was 5.5 months. Of the 29 patients who survived for more than two cycles of therapy, 22 (76%) achieved neutrophil recovery and 59% (n = 17) recovered also their platelet count. In 15 (52% of those who survived > 2 months), CR/CRi was confirmed by bone marrow examination. The median OS from venetoclax initiation of all the patients and of those who survived more than 2 months was 5.5 and 6.5 months, respectively. In conclusion, this study demonstrates that venetoclax is safe and active also in AML patients with advanced disease.

AB - Data from 11 Israeli centers, where venetoclax was used for relapsed/refractory AML after intensive chemotherapy, were retrospectively collected. During 2016–2019, forty patients were identified. Median age was 67 years (21–82), 60% males, median of 2(1–4) prior lines of treatment and 42% relapsed after allogeneic transplant. 62.5% of the patients received the venetoclax with hypomethylating agents and 22.5% with low dose cytarabine. Median follow-up was 5.5 months. Of the 29 patients who survived for more than two cycles of therapy, 22 (76%) achieved neutrophil recovery and 59% (n = 17) recovered also their platelet count. In 15 (52% of those who survived > 2 months), CR/CRi was confirmed by bone marrow examination. The median OS from venetoclax initiation of all the patients and of those who survived more than 2 months was 5.5 and 6.5 months, respectively. In conclusion, this study demonstrates that venetoclax is safe and active also in AML patients with advanced disease.

KW - Acute myeloid leukemia

KW - refractory

KW - relapse

KW - venetoclax

UR - http://www.scopus.com/inward/record.url?scp=85085324904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85085324904&partnerID=8YFLogxK

U2 - 10.1080/10428194.2020.1761964

DO - 10.1080/10428194.2020.1761964

M3 - Article

C2 - 32420775

AN - SCOPUS:85085324904

SN - 1042-8194

VL - 61

SP - 2221

EP - 2225

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 9

ER -

Venetoclax is safe and efficacious in relapsed/refractory AML

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this